CD19x22 CAR T

Phase 1Cell therapy

UUniversity of Colorado, Denver

CD19x22 CAR T is one of 33 biologic programs targeting Non-Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkin LymphomaRecruiting

Chimeric Antigen Receptor T-CellRecruiting

Non-Hodgkin LymphomaPhase 1

Recruiting

Chimeric Antigen Receptor T-CellPhase 1

Recruiting

Competition

Competitive Landscape

34 competitors in Non-Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

Polivy

Roche

Phase 3

2 3

LUNSUMIO

Roche

Phase 3

2 4

Actemra

CCelltrion

Phase 3

3 5

Epkinly

Genmab

Phase 2

3 6

Medrol

Pfizer

Phase 2

1 7

Adriamycin

Pfizer

Phase 2

1 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 9

Imbruvica

PPharmacyclics LLC.

Phase 2

2 10

Cytoxan

BBaxter Healthcare Corporation

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Non-Hodgkin Lymphoma

NCT05098613

Q4 2029

Phase 1Recruiting

Chimeric Antigen Receptor T-Cell

NCT06559189

Clinical

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06559189·53 enrolled

Non-Hodgkin Lymphoma1 trial

Phase 1 Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT05098613·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CD19x22 CAR T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19x22 CAR T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19x22 CAR T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Denver company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Colorado, Denver

CD19x22 CAR T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2029

Trials by Indication[1]

Chimeric Antigen Receptor T-cell1 trial

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News